These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 21968130)

  • 41. A summary of bortezomib use in transplantation across 29 centers.
    Everly MJ
    Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.
    Jordan SC; Reinsmoen N; Lai CH; Cao K; Kahwaji J; Peng A; Villicana R; Vo A
    Transplant Proc; 2012 Jan; 44(1):60-1. PubMed ID: 22310579
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
    Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
    Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
    [No Abstract]   [Full Text] [Related]  

  • 44. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal.
    Bierl C; Miller B; Prak EL; Gasiewski A; Kearns J; Tsai D; Jessup M; Kamoun M
    Clin Transpl; 2006; ():489-96. PubMed ID: 18365409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Preparation of highly HLA-sensitized patient for heart transplantation: first documented case in Croatia].
    Gavranić BB; Basić-Jukić N; Ratković-Gusić I; Martinez N; Ivancan V; Kes P
    Acta Med Croatica; 2011; 65(4):301-4. PubMed ID: 22359900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Pavlakis M
    Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Desensitization in kidney transplantation: review and future perspectives.
    Abu Jawdeh BG; Cuffy MC; Alloway RR; Shields AR; Woodle ES
    Clin Transplant; 2014 Apr; 28(4):494-507. PubMed ID: 24621089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
    Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bortezomib use in a pediatric cardiac transplant center.
    Zinn MD; L'Ecuyer TJ; Fagoaga OR; Aggarwal S
    Pediatr Transplant; 2014 Aug; 18(5):469-76. PubMed ID: 24931171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Donor-specific HLA antibodies after transplantation are associated with deterioration in cardiac function.
    Leech SH; Mather PJ; Eisen HJ; Pina IL; Margulies KB; Bove AA; Jeevanandam V
    Clin Transplant; 1996 Dec; 10(6 Pt 2):639-45. PubMed ID: 8996758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heart transplant graft survival is improved after a reduction in panel reactive antibody activity.
    Schaffer JM; Singh SK; Reitz BA; Oyer PE; Robbins RC; Mallidi HR
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):555-64; discussion 564-5. PubMed ID: 23246047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Desensitization protocols and their outcome.
    Marfo K; Lu A; Ling M; Akalin E
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):922-36. PubMed ID: 21441131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
    Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time?
    Kozlowski T; Andreoni K
    Ann Transplant; 2011; 16(2):19-25. PubMed ID: 21716181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
    Nguyen S; Gallay B; Butani L
    Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
    Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does bortezomib influence pre-transplant desensitization therapy or benefit post-heart transplant outcomes for highly sensitized patients?
    Dhillon M; Kobashigawa JA; Kittleson M; Jain R; Patel N; Singer-Englar T; Zhang X; Hakimi M; Aintablian T; Vescio R; Dilibero D; Kransdorf E; Czer L; Nikolova AP; Patel JK
    Clin Transplant; 2024 Jan; 38(1):e15165. PubMed ID: 37837612
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
    Cooper JE; Wiseman AC; Chan L
    Clin Transpl; 2009; ():455-9. PubMed ID: 20524314
    [No Abstract]   [Full Text] [Related]  

  • 60. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
    Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL
    Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.